ABSTRACT
La dieta baja en FODMAP ha mostrado ser una herramienta eficaz en el manejo de los síntomas del Síndrome de Intestino Irritable (SII). Los estudios recientes aleatorizados, controlados y prospectivos apoyan el uso de esta dieta como parte del tratamiento de esta patología. Los mecanismos mediante los que la dieta baja en FODMAP alivia los síntomas son variados y se relacionan con la fisiopatología del SII. Esta dieta puede generar cambios en la flora intestinal, efecto que aún no ha sido ampliamente estudiado.
The low FODMAP diet has been shown to be an efficacious therapy for reduction of functional gastrointestinal symptoms seen in Irritable Bowel Disease (IBS). Recent publications provide randomized controlled trial and prospective evidence in support of the diet for symptom management. The mecanisms of the low FODMAP diet to relief sympotms are assorted and in realtionship with the physiopathology of IBS. This diet can turno n changes in microbiota. This effect has not be completely understood. Further research to determine the potential health implications and microbiotal effect is required.
Subject(s)
Humans , Irritable Bowel Syndrome/diet therapy , Diet, Carbohydrate-Restricted , Polysaccharides/adverse effects , Diet Therapy , Monosaccharides/adverse effectsABSTRACT
Current study is to develop the colon targeted matrix tablet using the natural polysaccharide sterculia gum as carrier and model drug ciprofloxacin HCl. The matrix tablets were prepared by wet granulation technology using the various proportions of sterculia gum with carbopol 934 P, sterculia gum and ethyl cellulose polymer blends. Gra-nules of all formulations were evaluated for rheological, post compressional properties and in vitro dissolution study in different pH buffers of pH 1.2 , pH 7.4 , pH 6.8 (saline phosphate buffer) without and with 4% rat cecal content in order to mimic GIT condition . Formulation SGC2 to SGC4 and SGE7 to SGE9 has released 13.6% to 38.9% in the initial 5h and released more amount of drug in stomach and small intestine than colon. Formulation SGC5 containing 45% of sterculia gum and 25% carbopol 934 p and Formulation SGE10 containing 45% of sterculia gum and 25% ethyl cellulose has released minimum 10.91 % to 13.04 % in the initial 5h and sustained the drug release up to 24 h and at the end of study released 75% to 79.99%. Formulations with 4% rat cecal content at the end of 24 h study drug released is 90.44% to 95.33% indicating higher amount of drug release is due to enzymatic break down of sterculia gum in the matrix tablet. Hence the above results conclude that the formulation SGC5 and SGE10 are potential in targeting the drug to colon to treat irritable bowel disease.
ABSTRACT
Current study is to develop the colon targeted matrix tablet using the natural polysaccharide sterculia gum as carrier and model drug ciprofloxacin HCl. The matrix tablets were prepared by wet granulation technology using the various proportions of sterculia gum with carbopol 934 P, sterculia gum and ethyl cellulose polymer blends. Gra-nules of all formulations were evaluated for rheological, post compressional properties and in vitro dissolution study in different pH buffers of pH 1.2 , pH 7.4 , pH 6.8 (saline phosphate buffer) without and with 4% rat cecal content in order to mimic GIT condition . Formulation SGC2 to SGC4 and SGE7 to SGE9 has released 13.6% to 38.9% in the initial 5h and released more amount of drug in stomach and small intestine than colon. Formulation SGC5 containing 45% of sterculia gum and 25% carbopol 934 p and Formulation SGE10 containing 45% of sterculia gum and 25% ethyl cellulose has released minimum 10.91 % to 13.04 % in the initial 5h and sustained the drug release up to 24 h and at the end of study released 75% to 79.99%. Formulations with 4% rat cecal content at the end of 24 h study drug released is 90.44% to 95.33% indicating higher amount of drug release is due to enzymatic break down of sterculia gum in the matrix tablet. Hence the above results conclude that the formulation SGC5 and SGE10 are potential in targeting the drug to colon to treat irritable bowel disease.
ABSTRACT
Objective To determine whether platelet activation is associated with active ulcerative colitis (UC). Methods Platelet aggregability was assessed by means of SH 93 intelligent blood aggregation and coagulation tester; P selectin and thromboxane B 2 (TXB 2) were detected by means of ELISA method in patients with UC as well as in controls, including healthy volunteers and patients with irritable bowel syndrome (IBS). Colonoscopy and biopsy were performed in 43 patients with UC. Results Increased circulating platelet aggregability was detected in active ulcerative colitis compared with IBS and healthy controls ( P